These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38534207)

  • 1. Platform-Specific Fc
    Nador E; Xia C; Santangelo PJ; Whaley KJ; Costello CE; Anderson DJ
    Antibodies (Basel); 2024 Mar; 13(1):. PubMed ID: 38534207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women.
    Baldeon-Vaca G; Marathe JG; Politch JA; Mausser E; Pudney J; Doud J; Nador E; Zeitlin L; Pauly M; Moench TR; Brennan M; Whaley KJ; Anderson DJ
    EBioMedicine; 2021 Jul; 69():103478. PubMed ID: 34256345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity.
    Mausser E; Nador E; Politch JA; Pauly MR; Marathe JG; Moench TR; Zeitlin L; Whaley KJ; Anderson DJ
    PLoS One; 2023; 18(3):e0282147. PubMed ID: 36996137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.
    Chung AW; Crispin M; Pritchard L; Robinson H; Gorny MK; Yu X; Bailey-Kellogg C; Ackerman ME; Scanlan C; Zolla-Pazner S; Alter G
    AIDS; 2014 Nov; 28(17):2523-30. PubMed ID: 25160934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
    Wada R; Matsui M; Kawasaki N
    MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
    Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
    PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Dual-Approach Strategy to Optimize the Safety and Efficacy of Anti-Zika Virus Monoclonal Antibody Therapeutics.
    Sun H; Yang M; Lai H; Neupane B; Teh AY; Jugler C; Ma JK; Steinkellner H; Bai F; Chen Q
    Viruses; 2023 May; 15(5):. PubMed ID: 37243242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
    Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
    J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies.
    Kuhns S; Shu J; Xiang C; Guzman R; Zhang Q; Bretzlaff W; Miscalichi N; Kalenian K; Joubert M
    J Biotechnol; 2020 Jun; 317():5-15. PubMed ID: 32361021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
    Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
    Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
    Branstetter E; Duff RJ; Kuhns S; Padaki R
    FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody.
    Castilho A; Bohorova N; Grass J; Bohorov O; Zeitlin L; Whaley K; Altmann F; Steinkellner H
    PLoS One; 2011; 6(10):e26040. PubMed ID: 22039433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
    Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
    Front Immunol; 2017; 8():1554. PubMed ID: 29181010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and
    Nguyen KD; Kajiura H; Kamiya R; Yoshida T; Misaki R; Fujiyama K
    Front Plant Sci; 2023; 14():1215580. PubMed ID: 37615027
    [No Abstract]   [Full Text] [Related]  

  • 19. An oligosaccharyltransferase from
    Beihammer G; König-Beihammer J; Kogelmann B; Ruocco V; Grünwald-Gruber C; D'Aoust MA; Lavoie PO; Saxena P; Gach JS; Steinkellner H; Strasser R
    Front Plant Sci; 2023; 14():1233666. PubMed ID: 37615026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-based production of Fc-GlcNAc and Fc-alpha-2,6 sialyl glycan enriched antibody with improved effector functions through glycosylation pathway engineering.
    Huang HW; Shivatare VS; Tseng TH; Wong CH
    bioRxiv; 2023 Dec; ():. PubMed ID: 38187613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.